Tempus AI's stock soared 5.11% during intraday trading on Wednesday.

The surge follows the company's announcement of a new automated clinical update service designed to keep cancer therapy recommendations aligned with current guidelines without requiring new patient samples. Tempus AI also reported that 31 research abstracts have been accepted for presentation at the AACR 2026 conference, highlighting its expanding research footprint in AI-powered oncology.

In a separate development, Tempus AI entered into a collaboration with Predicta Biosciences to commercially expand access to an ultrasensitive whole-genome sequencing assay for hematologic cancers. The co-branded GenoPredicta assay aims to improve diagnosis and monitoring while reducing the need for invasive biopsies, representing a strategic expansion of the company's diagnostic offerings.